NAD and NMN claims: what the TGA's new guidance allows and what it does not

In short. NMN has been a permitted ingredient in listed medicines since 10 December 2025. NAD, NAD+ and NADH are not, and there are currently no permitted indications that refer to NAD or NMN levels. In August 2026 the TGA published guidance on how sponsors can talk about these ingredients. The headline: your product name, your claims and your website all count.

Ingredients: NMN yes, NAD no

Listed medicines can only contain permitted ingredients. NMN was added to the Ingredients Determination in December 2025, with conditions that must be met. NAD, NAD+ and NADH remain outside the list. Some NMN precursors, such as nicotinamide and nicotinamide riboside chloride, are also permitted, and the guidance applies to them too.

Indications: no NAD level claims

There are currently no permitted indications that refer to NAD, NAD+, NADH or NMN. Claims such as boosting or supporting NAD levels are not permitted indications, and using them on a label or in advertising may breach the Act.

Two kinds of statement

The TGA separates statements into those with no therapeutic use, such as "NAD+ is a coenzyme", and those that contain or imply one. The first type is usable if you hold evidence for it. The second needs a permitted indication of similar intent on the ARTG entry, plus evidence. Its examples of acceptable wording tie NMN to a permitted indication such as supporting energy levels, and it cautions that the wording alone does not guarantee compliance.

Statements that imply a benefit with no matching permitted indication are not acceptable. The TGA gives the example of saying that maintaining NAD levels is essential for cellular function and vitality.

Names

Product names that use NAD, NAD+, NADH or NMN can lead people to expect an ingredient or an indication that is not available. The TGA lists names such as NAD Booster, NAD+ 50 and NAD+ Enhance as unacceptable.

Your website is part of the product

The guidance treats a medicine's presentation as everything around it: the name, label, packaging, claims, and advertising including websites, blogs, social media, reviews and testimonials. It gives worked examples where a compliant label sits beside a webpage that implies an ageing or disease benefit, and the overall presentation fails. A label that is clean cannot rescue a page that overreaches, and corrective information buried in small print does not overcome a stronger primary message.

What to do

Review the ARTG entry, name, label, packaging and every page that markets the product, together rather than one at a time. Amend what does not align and stop supply of medicines that cannot meet the requirements. If you are unsure, take advice before the next print run or campaign.

This article is general information, not legal advice. Read the TGA guidance in full before you make changes.

1. TGA, Making NAD, NAD+, NADH or NMN representations for listed medicines (guidance for sponsors), 12 August 2026: tga.gov.au.
2. Therapeutic Goods (Permissible Ingredients) Determination and Permissible Indications Determination, as in force.
3. Therapeutic Goods Advertising Code, as in force.